Effects of Hydroxysafflor Yellow A on the PI3K/AKT Pathway and Apoptosis of Pancreatic β-Cells in Type 2 Diabetes Mellitus Rats

References

• Kahn SE, Cooper ME, Prato SD. Pathophysiol ogy and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–1083. doi:10.1016/S0140-6736(13)62154-6
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. doi:10.1007/s00125-017-4318-z
   PubMed Web of Science ®Google Scholar
• Zhang L, Tian K, Tang Z, et al. Phytochemistry and pharmacology of Carthamus tinctorius L. Am J Chin Med. 2016;44(2):197–226. doi:10.1142/S0192415X16500130
   PubMed Web of Science ®Google Scholar
• Asgary S, Rahimi P, Mahzouni P, Madani H. Antidiabetic effect of hydroalcoholic extract of Carthamus tinctorius L. in alloxan-induced diabetic rats. J Res Med Sci. 2012;17(4):386–392.
   PubMedGoogle Scholar
• Zhou X, Tang L, Xu Y, Zhou G, Wang Z. Towards a better understanding of medicinal uses of Carthamus tinctorius L. in traditional Chinese medicine: a phytochemical and pharmacological review. J Ethnopharmacol. 2014;151(1):27–43. doi:10.1016/j.jep.2013.10.050
   PubMed Web of Science ®Google Scholar
• Chu D, Liu W, Huang Z, Liu S, Fu X, Liu K. Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs. Planta Med. 2006;72(5):418–423. doi:10.1055/s-2005-916249
   PubMed Web of Science ®Google Scholar
• Tian J, Li G, Liu Z, Fu F. Hydroxysafflor yellow A inhibits rat brain mitochondrial permeability transition pores by a free radical scavenging action. Pharmacology. 2008;82(2):121–126. doi:10.1159/000141653
   PubMedGoogle Scholar
• Wu Y, Wang L, Jin M, Zang B. Hydroxysafflor yellow A alleviates early inflammatory response of bleomycin-induced mice lung injury. Biol Pharm Bull. 2012;35(4):515–522. doi:10.1248/bpb.35.515
   PubMedGoogle Scholar
• D B J, Zhang LY, C L L, Ye J, Zhu H. Effect of hydroxysafflor yellow A on human umbilical vein endothelial cells under hypoxia. Vascul Pharmacol. 2009;50(3–4):137–145. doi:10.1016/j.vph.2008.11.009
   PubMedGoogle Scholar
• Chen L, Xiang Y, Kong L, et al. Hydroxysafflor yellow A protects against cerebral ischemia–reperfusion injury by anti-apoptotic effect through PI3K/Akt/GSK3β pathway in rat. Neurochem Res. 2013;38(11):2268–2275. doi:10.1007/s11064-013-1135-8
   PubMed Web of Science ®Google Scholar
• Qi Z, Yan F, Shi W, et al. AKT-related autophagy contributes to the neuroprotective efficacy of hydroxysafflor yellow A against ischemic stroke in rats. Transl Stroke Res. 2014;5(4):501–509. doi:10.1007/s12975-014-0346-x
   PubMed Web of Science ®Google Scholar
• Srinivasan K, Viswanad B, Asrat L, Kaul C, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52(4):313–320. doi:10.1016/j.phrs.2005.05.004
   PubMed Web of Science ®Google Scholar
• Sahin K, Tuzcu M, Orhan C, et al. Anti-diabetic activity of chromium picolinate and biotin in rats with type 2 diabetes induced by high-fat diet and streptozotocin. Br J Nutr. 2013;110(2):197–205. doi:10.1017/S0007114512004850
   PubMedGoogle Scholar
• Reed MJ, Meszaros K, Entes LJ, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metab Clin Exp. 2000;49(11):1390–1394. doi:10.1053/meta.2000.17721
   PubMed Web of Science ®Google Scholar
• Skovso S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig. 2014;5(4):349–358. doi:10.1111/jdi.12235
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams KC, Stern MP, Haffner S. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease the San Antonio heart study. Diabetes Care. 2002;25(7):1177–1184. doi:10.2337/diacare.25.7.1177
   PubMed Web of Science ®Google Scholar
• Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med. 2012;237(5):481–490. doi:10.1258/ebm.2012.011372
   PubMed Web of Science ®Google Scholar
• Jiang B, Qu Z, Gu Y, et al. Renoprotective effect of JinQi-JiangTang tablet on high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats. RSC Adv. 2018;8(73):41858–41871. doi:10.1039/C8RA07858K
   PubMedGoogle Scholar
• Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer J, Spicer MT. High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J Nutr Biochem. 2008;19(8):505–513. doi:10.1016/j.jnutbio.2007.06.005
   PubMed Web of Science ®Google Scholar
• Ji G, Zhao X, Leng L, Liu P, Jiang Z. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis. 2011;10(1):23. doi:10.1186/1476-511X-10-23
   PubMedGoogle Scholar
• Barter PJ, Nicholls SJ, Rye K, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764–772. doi:10.1161/01.RES.0000146094.59640.13
   PubMed Web of Science ®Google Scholar
• Mi J, He W, Lv J, Zhuang K, Huang H, Quan S. Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1717–1725. doi:10.2147/DMSO.S211188
   PubMed Web of Science ®Google Scholar
• Atta MS, Elfar AH, Farrag F, Abdeldaim MM, Jaouni SK, Mousa SA. Thymoquinone attenuates cardiomyopathy in streptozotocin-treated diabetic rats. Oxid Med Cell Longev.2018;2018:7845681. doi:10.1155/2018/7845681
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu Y, Yang Y, et al. Transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin‑treated sprague‑dawley rats with type 2 diabetes mellitus. Int J Mol Med. 2018;41(6):3327–3341. doi:10.3892/ijmm.2018.3535
   PubMedGoogle Scholar
• Li H, Liu Y, Wen M, et al. Hydroxysafflor yellow A (HSYA) alleviates apoptosis and autophagy of neural stem cells induced by heat stress via p38 MAPK/MK2/Hsp27-78 signaling pathway. Biomed Pharmacother. 2019;114:108815.biopha.2019.108815. doi:10.1016/j.biopha.2019.108815.
   Google Scholar
• Juan B, Jinyi Z, Dongxiao C, et al. Protective effect of hydroxysafflor yellow A against acute kidney injury via the TLR4/NF-κB signaling pathway. Sci Rep. 2018;8(1):9173. doi:10.1038/s41598-018-27217-3
   PubMedGoogle Scholar
• Nandipati KC, Subramanian S, Agrawal DK. Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. Mol Cell Biochem. 2017;426(1–2):27–45. doi:10.1007/s11010-016-2878-8
   PubMed Web of Science ®Google Scholar
• Nana W, Tiegang L, Ping H. The effect of tianmai xiaoke pian on insulin resistance through PI3-K/AKT signal pathway. J Diabetes Res. 2016;2016:1–8.
   Google Scholar
• Yu N, Fang X, Zhao D, et al. Anti-diabetic effects of Jiang Tang Xiao Ke granule via PI3K/Akt signalling pathway in type 2 diabetes KKAy mice. PLoS One. 2017;12(1):e0168980. doi:10.1371/journal.pone.0168980
   PubMed Web of Science ®Google Scholar
• Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005;6(8):777–784. doi:10.1038/ni1221
   PubMed Web of Science ®Google Scholar
• Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29(2):95–102. doi:10.1016/j.tibs.2003.12.004
   PubMed Web of Science ®Google Scholar
• Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol. 2005;17(2):150–157. doi:10.1016/j.ceb.2005.02.010
   PubMed Web of Science ®Google Scholar
• Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–131. doi:10.1016/j.pharmthera.2014.11.016
   PubMed Web of Science ®Google Scholar
• Liu Z, Li C, Li M, et al. The subchronic toxicity of hydroxysafflor yellow A of 90 days repeatedly intraperitoneal injections in rats. Toxicol. 2004;203(1–3):139–143. doi:10.1016/j.tox.2004.06.007
   PubMed Web of Science ®Google Scholar
• Zhang HF, Guo JX, Huang LS, et al. Pharmacokinetics of hydroxysafflor yellow A in rats. J China Pharm Univ. 2006;37(5):456–460.
   Google Scholar
• Tian Y, Yang ZF, Li Y, et al. Pharmacokinetic comparisons of hydroxysafflower yellow A in normal and blood stasis syndrome rats. J Ethnopharmacol. 2010;129(1):0–4. doi:10.1016/j.jep.2010.02.023
   Google Scholar
• Liu J, Yue S, Yang Z, et al. Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism. Pharmacol Res. 2018;134:40–50. doi:10.1016/j.phrs.2018.05.012
   PubMed Web of Science ®Google Scholar